

Univercells and Exothera announce Thibault Jonckheere as new CEO of Exothera

Brussels, Belgium, June 1, 2021

Univercells S.A. (“Univercells”) and Exothera S.A. (the “Company”) are pleased to announce that effective June 1, 2021, Thibault Jonckheere has been appointed as Chief Executive Officer of Exothera, a Univercells company and uniquely positioned full-service viral vector Contract Development and Manufacturing Organization (CDMO). The appointment of Thibault is the next step in driving Exothera to realize its vision of making cell and gene therapies (C>) available to all.

Thibault joined Exothera as Deputy Chief Executive Officer following last year’s carve-out of the Company from Univercells. The Company has since experienced rapid growth, more than tripling its number of collaborators to over one hundred. The beginning of this year also marked the signing of Exothera’s first contracts, including a development agreement with CyanVac LLC for its Covid-19 intranasal vaccine candidate, which will be manufactured at Exothera’s Jumet plant expected to be GMP-certified by early H2 2021.

Thibault started his career in the energy sector, holding several financial and consultancy positions. He joined the leading cell therapy CDMO, MaSTherCell, in 2013 as Corporate and Business Development Manager, generating revenue streams of several millions and driving the organization to profitability. In 2016, Thibault joined ImmunXperts, an immunology Contract Research Organization, where he developed the company from the ground up until its sale to Nexelis at the beginning of 2020.

Thibault holds a Master of Business Engineering from the Solvay Brussels School of Economics and Management.

Hugues Bultot, CEO of Univercells commented: “Univercells has become an incubator for talent, of which the appointment of Thibault as the new CEO of our spinoff Exothera is another wonderful example. The Board and I are confident that Thibault’s international background in business engineering, operations, and business development will enable him to lead the continued expansion of Exothera successfully.”

Thibault Jonckheere addressed his new role, adding: "Together with the rest of the team, I’m very much looking forward to leading Exothera into its next development phase, beginning with the much-anticipated GMP certification, expected this summer. By expanding our expertise, we enable our clients to bring their products to market, thereby realizing our ambitious vision of bringing life-changing therapies to all."

||| **About Univercells** |||

Univercells is a global life sciences company that makes biologics available to all. Leveraging our core strengths in scaling, production, and bioprocessing, we build businesses and find new ways to support access to medicines and promote sustainability. Through entrepreneurship and technology-driven affordability, we address the needs of the entire health value chain.

Univercells is headquartered in Gosselies (Belgium) and benefits from the support of regional and national investors, as well as international investors, such as the Bill & Melinda Gates Foundation, EIB, Global Health Investment Fund, among others active in the health and vaccine industry.

www.univercells.com

||| **About Exothera** |||

Exothera is a uniquely positioned viral vector CDMO (contract manufacturing and development organization) that rapidly delivers affordable gene therapies and viral vector-based vaccines. As a Univercells company, Exothera capitalizes on novel manufacturing technologies and best-in-class bioprocessing expertise to provide bespoke process optimization and GMP clinical and commercial production of viral vectors. Based on its extensive technology expertise, Exothera select adapted technologies to optimally answer customer needs for cost-effective and agile viral vector manufacturing.

www.exothera.world

||| **Disclosure Statement** |||

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified using forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties, and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.